ImmunoGen Inc.

426 articles with ImmunoGen Inc.

• ImmunoGen Presents New Data Highlighting Potential of Novel ADCs in Oral Presentations at ASH Annual Meeting

  12/1/2018

  ImmunoGen, Inc., (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that new data from the ongoing Phase 1 studies of IMGN632 and IMGN779, next-generation CD123- and CD33-targeting ADCs

• ImmunoGen Announces Resignation of Chief Financial Officer

  11/26/2018

  ImmunoGen, Inc., (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that David B. Johnston has stepped down as Chief Financial Officer of the Company, with immediate effect

• Over 76 Data Driven Presentations on Cancer Treatment Research to be Presented at the 9th Annual World Antibody-Drug Conjugate Conference in San Diego, November 12-15

  11/8/2018

  The Antibody-Drug Conjugate community will join together for the 9th World ADC San Diego on November 12-15 at the Marriott Marquis San Diego with key influential researchers from around the world, to discuss clinical research experiences to help further the development of cancer therapeutics.

• ImmunoGen Announces Webcasts of Presentations at Upcoming November 2018 Conferences

  11/6/2018

  ImmunoGen, Inc. today announced that the following presentations by Company management at upcoming investor conferences will be webcast:

• ImmunoGen Reports Recent Progress and Third Quarter 2018 Operating Results

  11/2/2018

  Initial Data from FORWARD II Expansion Cohort of Mirvetuximab Soravtansine with KEYTRUDA® Reported at ESMO

• ImmunoGen to Present New Data on Novel Antibody-Drug Conjugates at 60th ASH Annual Meeting

  11/1/2018

  ImmunoGen Inc., (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that abstracts highlighting two of the Company’s experimental ADC therapies, IMGN779 and IMGN632, have been accepted for presentations at the upcoming American Society of Hematology (ASH) Annual Meeting to be held December 1-4 in San Diego, California.

• ImmunoGen Presents Initial Data from FORWARD II Expansion Cohort Assessing Mirvetuximab Soravtansine in Combination with KEYTRUDA at ESMO 2018 Congress

  10/20/2018

  ImmunoGen Inc, today announced initial safety and preliminary anti-tumor activity from the FORWARD II expansion cohort assessing mirvetuximab soravtansine

• ImmunoGen Announces Conference Call to Discuss Its Third Quarter 2018 Operating Results

  10/18/2018

  ImmunoGen, Inc. today announced that Company will host a conference call at 8:00a.m. on Friday, Nov 2, 2018.

• ImmunoGen to Present Initial Data from FORWARD II Expansion Cohort of Mirvetuximab Soravtansine in Combination with KEYTRUDA at ESMO

  10/8/2018

  ImmunoGen, Inc. today announced that initial findings from the FORWARD II expansion cohort of mirvetuximab soravtansine in combination with Merck’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), will be presented at the European Society for Medical Oncology (ESMO) Congress from October 19-23, 2018 in Munich, Germany.

• 

  Tesaro Highlights Benefits of Maintenance Therapy Zejula During Ovarian Cancer Awareness Month

  9/25/2018

  Ovarian cancer is the fifth leading cause of cancer-related deaths in the United States. It is estimated that this year there will be more than 22,000 women in the U.S. diagnosed with the disease and about 14,000 disease-related deaths.

• ImmunoGen Announces Webcasts of Presentations at Upcoming October 2018 Conferences

  9/24/2018

  ImmunoGen, Inc. today announced that the following presentations by Company management at upcoming investor conferences will be webcast:

• 

  Movers and Shakers for Sept. 10

  9/10/2018

  Let's take a look at who made a splash in the pharma and biotech world the past week.
• 

  13 Massachusetts Life Science Companies Show Gains and Losses

  8/14/2018

  Massachusetts in general and Boston, specifically Cambridge, is one of the two largest centers in the U.S. for biotech startups and life science companies (the other being the San Francisco Bay Area). Here’s a look at 13 Massachusetts life science companies that are showing both gains and losses—...

• AIT Bioscience’s Terri Pascarelli Recognized as a 2018 PharmaVOICE 100 honoree

  8/3/2018

  AIT Bioscience, LLC Chief Executive Officer, Terri Pascarelli has been named among the 2018 PharmaVOICE 100 honorees.

• ImmunoGen Reports Recent Progress and Second Quarter 2018 Operating Results

  7/27/2018

  Mirvetuximab Soravtansine Granted Fast Track Designation by FDA

• ImmunoGen Announces FDA Fast Track Designation for Mirvetuximab Soravtansine in Patients with Platinum-Resistant Ovarian Cancer

  6/18/2018

  The designation is for the treatment of patients with medium to high folate receptor alpha (FRα)-positive platinum-resistant ovarian cancer who received at least one, but no more than three prior systemic treatment regimens, and for whom single-agent chemotherapy is appropriate as the next line of therapy.

• ImmunoGen Announces Closing of Public Offering of Common Stock

  6/11/2018

  ImmunoGen Inc., Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced the closing of its previously announced underwritten public offering of 13,700,000 shares of its common stock at a price to the public of $11.00 per share.

• ImmunoGen Announces Pricing of Upsized Public Offering of Common Stock

  6/7/2018

  ImmunoGen, Inc. today announced the pricing of an upsized underwritten public offering of 13,700,000 shares of its common stock at a price of $11.00 per share.

• ImmunoGen Announces Proposed Public Offering of 12,000,000 Shares of Common Stock

  6/5/2018

  ImmunoGen, Inc. announced that it intends to offer and sell, subject to market and other conditions, 12,000,000 shares of its common stock in an underwritten public offering.

• ImmunoGen Announces Webcast of Presentation at Jefferies 2018 Global Healthcare Conference

  5/30/2018

  ImmunoGen, Inc. announced that the Company will present at the upcoming Jefferies 2018 Global Healthcare Conference.